诺诚健华（09969）今日盘中大涨5.05%，引起了市场的广泛关注。
消息面上，诺诚健华此前发布的2025年年报显示，公司业绩表现强劲，主营收入23.75亿元，同比大幅上升135.27%；归母净利润6.42亿元，同比飙升245.81%。此外，数据显示主力资金近期呈现净流入状态，融资净买入也较为活跃，这些积极的基本面因素共同提振了市场信心，推动了股价的上涨。
诺诚健华主营业务为生物医药研发、生产和商业化，专注于肿瘤和自身免疫性疾病领域。公司产品管线丰富，包括奥布替尼、ICP-723等多款在研或已上市药物。近期，多家机构给予公司买入或增持评级，反映了市场对其未来发展的看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.